Urbaniak-Kujda et al. posited TIMP-2 contributes to carcinogenesis, disease progress, and the development of osseous lesions in a study evaluated the utility of TIMP-2 as a a biomarker for kidney injury in myeloma [15]. Here, TIMP2 is linked to plasma cell myeloma.